» Articles » PMID: 33011737

Comparison of Pharmacokinetics of Omega-3 Fatty Acid Supplements in Monoacylglycerol or Ethyl Ester in Humans: a Randomized Controlled Trial

Overview
Journal Eur J Clin Nutr
Date 2020 Oct 4
PMID 33011737
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A diet low in omega-3 fatty acids (n-3 FA) results in low plasma concentrations of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), the two main long chain n-3 FA. n-3 FA supplements on the market are esterified in triglycerides (TG) or ethyl ester (EE); the latter is absorbed less than other esterification forms. The objective of this study was to test and compare the pharmacokinetics of n-3 FA esterified in monoacylglycerides (MAG), a predigested form, with the EE form.

Methods: This study was a randomized, double-blind, crossover, controlled, clinical trial. Ten men and ten women between 18 and 60 years old were recruited. Participants received a single oral dose of 3 g of n-3 FA esterified in EE or MAG. Eleven blood samples were collected over 24 h post-dose. Plasma total lipids were extracted, methylated, and analyzed using gas chromatography.

Results: After receiving the MAG form, plasma EPA and DHA peaked at a concentration 3 and 2.5 times higher, respectively, than with the EE form. When provided in MAG form, n-3 FA plasma concentration during the absorption phase was on average 3-5 times higher than in EE form. When n-3 FAs were provided esterified in MAG, their concentration 24 h post-dose was higher than in EE. Males had a lower n-3 FA plasma concentration than females when n-3 FAs were provided in EE but there was no sexe difference when provided in MAG.

Conclusions: Plasma concentration of DHA and EPA was higher when provided in MAG than EE form.

Citing Articles

Predigested Mixture of Arachidonic and Docosahexaenoic Acids for Better Bio-Accessibility.

Chabni A, Pardo de Donlebun B, Romero M, Torres C Mar Drugs. 2024; 22(5).

PMID: 38786615 PMC: 11123075. DOI: 10.3390/md22050224.


Docosahexaenoic acid-loaded nanoparticles: A state-of-the-art of preparation methods, characterization, functionality, and therapeutic applications.

Ali A, Hachem M, Ahmmed M Heliyon. 2024; 10(9):e30946.

PMID: 38774069 PMC: 11107210. DOI: 10.1016/j.heliyon.2024.e30946.


A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.

Robitaille K, Guertin M, Jamshidi A, Xu H, Hovington H, Pelletier J Commun Med (Lond). 2024; 4(1):56.

PMID: 38519581 PMC: 10960033. DOI: 10.1038/s43856-024-00456-4.


Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid-Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis.

Loukil I, Aguilera E, Vachon A, Leveille P, Plourde M J Nutr. 2024; 154(5):1561-1570.

PMID: 38513888 PMC: 11130699. DOI: 10.1016/j.tjnut.2024.03.013.


New light on ω-3 polyunsaturated fatty acids and diabetes debate: a population pharmacokinetic-pharmacodynamic modelling and intake threshold study.

Wang L, Huang X, Sun M, Zheng T, Zheng L, Lin X Nutr Diabetes. 2024; 14(1):8.

PMID: 38438344 PMC: 10912742. DOI: 10.1038/s41387-024-00262-w.